Gut Inc.
Industry / private company
Location:
Kochi,
Japan (JP)
Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study (2024)
Suzuki K, Sameshima Y, Yokoyama J, Terai S, Yoneyama H, Atreya R, Neurath M, et al.
Journal article
Submucosal Injection of the RNA Oligonucleotide GUT-1 in Active Ulcerative Colitis Patients: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Induction Trial. (2024)
Atreya R, Kühbacher T, Waldner M, Hirschmann S, Drvarov O, Abu Hashem R, Maaser C, et al.
Journal article